Greenleaf Trust Purchases 2,429 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Greenleaf Trust lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,491 shares of the biopharmaceutical company’s stock after buying an additional 2,429 shares during the period. Greenleaf Trust’s holdings in Gilead Sciences were worth $3,280,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. PCA Investment Advisory Services Inc. acquired a new position in Gilead Sciences in the 2nd quarter worth $25,000. OFI Invest Asset Management acquired a new position in Gilead Sciences in the 3rd quarter worth $26,000. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC acquired a new position in Gilead Sciences in the 4th quarter worth $29,000. Finally, Rakuten Securities Inc. acquired a new position in Gilead Sciences in the 4th quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on GILD. StockNews.com downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. Mizuho reduced their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Wells Fargo & Company reduced their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Royal Bank of Canada reduced their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Finally, Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $84.71.

Gilead Sciences Stock Up 0.9 %

Gilead Sciences stock opened at $66.76 on Friday. The stock has a market cap of $83.12 billion, a P/E ratio of 14.84, a P/E/G ratio of 0.91 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a twelve month low of $65.90 and a twelve month high of $87.86. The company’s 50-day moving average price is $71.96 and its two-hundred day moving average price is $76.53.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.67 earnings per share. As a group, analysts expect that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.77 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.61%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.